Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYSLTR1 | Q9Y271 | 4/20 | 0.44 |
| ▸ | CYSLTR2 | Q9NS75 | 2/20 | 0.44 |
| ▸ | NCF1 | P14598 | 4/20 | 0.43 |
| ▸ | PDE3B | Q13370 | 6/20 | 0.42 |
| ▸ | PDE3A | Q14432 | 6/20 | 0.42 |
| ▸ | PDE2A | O00408 | 5/20 | 0.42 |
| ▸ | P2RY12 | Q9H244 | 4/20 | 0.42 |
| ▸ | NPC1 | O15118 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 1/20 | 0.41 |
| ▸ | RAB9A | P51151 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
| ▸ | APP | P05067 | 1/20 | 0.40 |
| ▸ | PTPN7 | P35236 | 1/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
| ▸ | GPBAR1 | Q8TDU6 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6834524 | 0.76 | CYSLTR1 (0.41) | CYSLTR1CYSLTR2NCF1PTPN7KDM4E | |
| SCHEMBL1641523 | 0.75 | HDAC1 (0.52) | MAPTKDM4EALDH1A1 | |
| SCHEMBL8146789 | 0.73 | NPC1 (0.66) | NCF1NPC1MAPTRAB9ASMN1; SMN2 | |
| SCHEMBL27559613 | 0.72 | KDM4E (0.40) | CYSLTR1CYSLTR2KDM4EALDH1A1GPBAR1 | |
| SCHEMBL4720632 | 0.72 | HDAC1 (0.51) | MAPTRAB9ASMN1; SMN2KDM4EALDH1A1 | |
| SCHEMBL9232392 | 0.71 | PTGS1 (0.41) | CYSLTR1MAPTKDM4EALDH1A1GPBAR1 | |
| Anthracene SCHEMBL10418177 | 0.70 | CYP1A2 (0.59) | CYSLTR1CYSLTR2KDM4EALDH1A1GPBAR1 | |
| SCHEMBL5108700 | 0.70 | PLA2G4B (0.55) | SMN1; SMN2KDM4EALDH1A1 | |
| SCHEMBL4476421 | 0.69 | NPC1 (0.53) | NCF1NPC1MAPTRAB9ASMN1; SMN2 | |
| SCHEMBL5470951 | 0.69 | BACE1 (0.51) | KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050090498-A1 | 3-Quinolin-2(1h)-ylideneindolin-2-one derivative | YAMANOUCHI PHARMACEUTICAL CO., LTD. (JP) | 2005-04-28 | — | — | US | disclosed |
| EP-1396490-A1 | 3-QUINOLINE-2-(1H)-YLIDENEINDOLIN-2-ONE DERIVATIVES | YAMANOUCHI PHARMACEUTICAL CO. LTD. (JP) | 2004-03-10 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050090498-A1 | 3-Quinolin-2(1h)-ylideneindolin-2-one derivative | KDR, FLT4, FLT1 | CYSLTR1 3870/4885CYSLTR2 3142/4885NCF1 1175/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.